

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA MEDICAL SYSTEM HOLDINGS LIMITED
康哲藥業控股有限公司*

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 867)

Voluntary and Business Update Announcement
Desidustat Tablets Being Granted an Approval for Drug Clinical Trial

China Medical System Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Desidustat Tablets of the Group licensed in from Cadila Healthcare Limited (“**Zydus**”) on 20 January 2020, has been granted an approval for drug clinical trial issued on 18 January 2021 from the National Medical Products Administration of the People’s Republic of China and agreed to carry out clinical trials for indication of anemia (including dialysis and non-dialysis patients) caused by chronic kidney disease (CKD).

Desidustat Tablets are novel oral Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) for treating anemia in CKD patients.

The Group is currently actively preparing for initiating the relevant clinical trials.

This is a voluntary announcement issued by the Company. Shareholders and investors are advised to exercise caution when dealing in the shares and other securities of the Company.

By order of the Board
China Medical System Holdings Limited
Lam Kong
Chairman

Hong Kong, 19 January 2021

As at the date of the announcement, the directors of the Company comprise (i) Mr. Lam Kong, Mr. Chen Hongbing and Ms. Chen Yanling as executive Directors; and (ii) Mr. Wu Chi Keung, Mr. Leung Chong Shun and Ms. Luo, Laura Ying as independent non-executive Directors.